# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents (NASDAQ:CTSO) with a Neutral and maintains $1 price target.
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) ...
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Better hemodynamic stability and lower rates of post-operative shock Patients in the CytoSorb group had lower median Vaso...
HC Wainwright & Co. analyst Sean Lee downgrades CytoSorbents (NASDAQ:CTSO) from Buy to Neutral and lowers the price targ...